Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
Quick facts
Marketed products
- High-Dose Dexamethasone · Immunology, Rheumatology, Endocrinology
High-dose dexamethasone is a potent synthetic glucocorticoid that suppresses the immune system and reduces inflammation by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Phase 3 pipeline
- COVID19 convalescent plasma infusion · Immunology / Infectious Disease
COVID-19 convalescent plasma infusion transfers antibodies and immune factors from recovered patients to provide passive immunotherapy against SARS-CoV-2.
Phase 2 pipeline
- Bivalent RBD-based ARVAC-CG vaccine · Vaccines
ARVAC-CG vaccine targets the RBD of SARS-CoV-2 - Gamma Variant RBD-based ARVAC-CG vaccine
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno portfolio CI brief
- Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno pipeline updates RSS
Frequently asked questions about Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno
What are Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno's marketed drugs?
Top marketed products include High-Dose Dexamethasone.
What is Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno's pipeline?
Centro de Educación Medica e Investigaciones Clínicas Norberto Quirno has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include COVID19 convalescent plasma infusion.
Related
- High-Dose Dexamethasone · Immunology, Rheumatology, Endocrinology
- Sector hub: All tracked pharma companies